Acrivon Therapeutics shares surge 30.17% premarket ahead of updated ACR-368 data and early ACR-2316 tumor-shrinkage results presentation.

Acrivon Therapeutics (ACRV) surged 30.17% in premarket trading following the announcement of updated clinical data for ACR-368, its Phase 2b candidate for endometrial cancer, and early results for ACR-2316, a dual WEE1/PKMYT1 inhibitor showing tumor shrinkage in Phase 1 trials. The company highlighted ACR-368’s FDA Fast Track designation and plans to present the data during a webcast on January 8, 2026, while emphasizing its robust $134.4 million cash reserves, which extend operational funding through mid-2027. Despite recent analyst downgrades (e.g., JonesResearch to Hold, Oppenheimer lowering price targets), the premarket rally suggests investor optimism about the pipeline’s therapeutic potential and the company’s financial stability. The positive momentum aligns with the anticipated validation of Acrivon’s AP3 platform through ACR-2316’s early-stage efficacy.